| 4.34 -0.01 (-0.23%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.35 |
1-year : | 8.99 |
| Resists | First : | 6.29 |
Second : | 7.69 |
| Pivot price | 4.9 |
|||
| Supports | First : | 4.01 | Second : | 3.34 |
| MAs | MA(5) : | 4.32 |
MA(20) : | 5.1 |
| MA(100) : | 10.03 |
MA(250) : | 26.22 |
|
| MACD | MACD : | -0.9  |
Signal : | -0.9 |
| %K %D | K(14,3) : | 14.6 |
D(3) : | 10 |
| RSI | RSI(14): 32.5 |
|||
| 52-week | High : | 84.8 | Low : | 0.71 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AEMD ] has closed above bottom band by 21.3%. Bollinger Bands are 71.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 34 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.5 - 4.53 | 4.53 - 4.55 |
| Low: | 4.09 - 4.12 | 4.12 - 4.15 |
| Close: | 4.29 - 4.34 | 4.34 - 4.38 |
Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
Tue, 11 Nov 2025
Aethlon Medical Q2 2026 Earnings Preview - MSN
Fri, 07 Nov 2025
Aethlon Medical Inc expected to post a loss of $3.66 a share - Earnings Preview - TradingView
Fri, 07 Nov 2025
Aethlon Medical (NASDAQ: AEMD) sets Nov. 12 results release; call 4:30 p.m. ET - Stock Titan
Fri, 07 Nov 2025
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 - Yahoo Finance
Fri, 07 Nov 2025
Aethlon Medical Regains Nasdaq Compliance After Stock Surge - The Globe and Mail
Wed, 29 Oct 2025
Aethlon Medical (AEMD) Price Target Increased by 309.09% to 12.62 - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 3.3 (%) |
| Held by Institutions | 5.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 5 (K) |
| EPS | -66.7 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 13.17 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -63.7 % |
| Return on Equity (ttm) | -207.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.75 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.07 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|